Sarepta Therapeutics (SRPT)

Sarepta’s approved DMD portfolio includes exon-skipping therapies such as EXONDYS 51, VYONDYS 53, and AMONDYS 45. These medicines are intended for patients with specific genetic mutations that may be amenable to skipping certain exons in the dystrophin gene, a strategy aimed at enabling production of a shortened but potentially functional form of dystrophin. The company is also associated with ELEVIDYS, a gene therapy developed for DMD that seeks to deliver a micro-dystrophin construct using an adeno-associated virus vector.

Beyond its marketed products, Sarepta maintains a pipeline of candidates for neuromuscular and other rare genetic diseases. Its research and development work spans gene therapy platforms, RNA technologies, manufacturing, regulatory strategy, and clinical development. Because rare disease drug development often targets small patient populations with high unmet medical need, clinical trial design, safety monitoring, reimbursement, and regulatory decisions are central to the company’s outlook.

SRPT is a biotechnology stock rather than a conventional healthcare services company. Its valuation is shaped by product sales, label expansions, pipeline progress, clinical data, manufacturing capabilities, intellectual property, and interactions with regulators. Sarepta stands out for its focused role in DMD treatment and its broader ambition to build a genetic medicine platform for rare diseases where few effective options exist.